Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-11-06

Clinical Trial Update: A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease [Phase 3]

View source ↗

Summary

Phase 3 trial of ferumoxytol for treating iron deficiency anemia in pediatric chronic kidney disease patients was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • FERUMOXYTOL (ferumoxytol)

Snippet

Sponsor: AMAG Pharmaceuticals, Inc. | Conditions: Iron Deficiency Anemia | Phase 3 | Status: TERMINATED | Results posted: 2017-11-06